NOV Stock Chart & Stats
CHF173.42
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF173.42
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF173.23 - CHF174.39
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
CHF169.56B
Enterprise ValueCHF1.49M
Total Cash (Recent Filing)CHF41.55B
Total Debt (Recent Filing)CHF118.72B
Price to Earnings (P/E)11.2
BetaN/A
Next Earnings
Nov 04, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)23.51
Shares Outstanding3,390,128,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF37.45Price Target Upside-78.41% Downside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNovo Nordisk's trial for Rybelsus in Alzheimer's could be clinically meaningful even with modest benefits, thanks to its broad safety profile.
Product StrategyNovo Nordisk is proactively engaging with physicians to optimize dosing strategies, which could enhance the safety and tolerability profile of its products.
Regulatory ProgressNovo Nordisk confirmed the filing of the Semaglutide 7.2mg dose in the US, indicating regulatory progress.
Bears Say
Financial GuidanceNovo announced an EBIT guide cut on restructuring costs, with the guide range lowered significantly, making the net benefit unclear.
Growth ExpectationsThe company is not viewed as a 'premium' growth entity anymore, with debates expected around the trading price-to-earnings multiple into the future.
Prescription TrendsThere is a lack of growth in prescription trends for Wegovy and Ozempic, with market pressure anticipated from patent expiry and competitor launches.
Novo Nordisk News
NOV FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was CHF173.23 and its highest was CHF174.39 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is CHF169.56B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Nov 04, 2026 which is in 87 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Aug 04, 2026. The company reported CHF0.774 earnings per share for the quarter, beating the consensus estimate of CHF0.63 by CHF0.144.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Overvalued.
Does Novo Nordisk pay dividends?
Novo Nordisk does not currently pay dividends.
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.62.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of CHF0.774 in its last earnings report, beating expectations of CHF0.63. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in CH:NOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novo Nordisk
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
NOV Stock 12 Month Forecast
Average Price Target
CHF37.45
▼(-78.41% Downside)